{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:38:29Z","timestamp":1781023109967,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008637","name":"Center for Strategic Scientific Initiatives, National Cancer Institute","doi-asserted-by":"publisher","award":["SC1CA200517"],"award-info":[{"award-number":["SC1CA200517"]}],"id":[{"id":"10.13039\/100008637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1SC1GM121202"],"award-info":[{"award-number":["1SC1GM121202"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1SC2CA235066"],"award-info":[{"award-number":["1SC2CA235066"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The abnormal PI3K\/AKT\/mTOR pathway is one of the most common genomic abnormalities in breast cancers including triple-negative breast cancer (TNBC), and pharmacologic inhibition of these aberrations has shown activity in TNBC patients. Here, we designed and identified a small-molecule Comp34 that suppresses both AKT and mTOR protein expression and exhibits robust cytotoxicity towards TNBC cells but not nontumorigenic normal breast epithelial cells. Mechanically, long noncoding RNA (lncRNA) AL354740.1-204 (also named as NUDT3-AS4) acts as a microRNA sponge to compete with AKT1\/mTOR mRNAs for binding to miR-99s, leading to decrease in degradation of AKT1\/mTOR mRNAs and subsequent increase in AKT1\/mTOR protein expression. Inhibition of lncRNA-NUDT3-AS4 and suppression of the NUDT3-AS4\/miR-99s association contribute to Comp34-affected biologic pathways. In addition, Comp34 alone is effective in cells with secondary resistance to rapamycin, the best-known inhibitor of mTOR, and displays a greater in vivo antitumor efficacy and lower toxicity than rapamycin in TNBC xenografted models. In conclusion, NUDT3-AS4 may play a proproliferative role in TNBC and be considered a relevant therapeutic target, and Comp34 presents promising activity as a single agent to inhibit TNBC through regulation of NUDT3-AS4 and miR-99s.<\/jats:p>","DOI":"10.1038\/s41419-020-03235-w","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T18:03:14Z","timestamp":1607709794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA"],"prefix":"10.1038","volume":"11","author":[{"given":"Qiongyu","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranabananda","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Schrode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Elshimali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Vadgama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1698-0897","authenticated-orcid":false,"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"issue":"6","key":"3235_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/PAP.0b013e3181594733","volume":"14","author":"LK Diaz","year":"2007","unstructured":"Diaz, L. K., Cryns, V. L., Symmans, W. F. & Sneige, N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv. Anat. Pathol. 14(6), 419\u2013430 (2007).","journal-title":"Adv. Anat. Pathol."},{"issue":"4","key":"3235_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.breast.2007.11.031","volume":"17","author":"H Mersin","year":"2008","unstructured":"Mersin, H., Yildirim, E., Berberoglu, U. & Gulben, K. The prognostic importance of triple negative breast carcinoma. Breast 17(4), 341\u2013346 (2008).","journal-title":"Breast"},{"issue":"7418","key":"3235_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"N Cancer Genome Atlas","year":"2012","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61\u201370 (2012).","journal-title":"Nature"},{"issue":"6","key":"3235_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/07853890.2014.912836","volume":"46","author":"M Martini","year":"2014","unstructured":"Martini, M. et al. PI3K\/AKT signaling pathway and cancer: an updated review. Ann. Med. 46(6), 372\u2013383 (2014).","journal-title":"Ann. Med."},{"issue":"31","key":"3235_CR5","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso, P. M. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J. Clin. Oncol. 34(31), 3803\u20133815 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"3235_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2011.09.028","volume":"147","author":"M Cesana","year":"2011","unstructured":"Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147(2), 358\u2013369 (2011).","journal-title":"Cell"},{"issue":"7441","key":"3235_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. Nature 495(7441), 384\u2013388 (2013).","journal-title":"Nature"},{"issue":"3","key":"3235_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","volume":"146","author":"L Salmena","year":"2011","unstructured":"Salmena, L. et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146(3), 353\u2013358 (2011).","journal-title":"Cell"},{"key":"3235_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3914","volume":"5","author":"ZJ Rutnam","year":"2014","unstructured":"Rutnam, Z. J. et al. The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs. Nat. Commun. 5, 2914 (2014).","journal-title":"Nat. Commun."},{"issue":"2","key":"3235_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cell.2015.02.043","volume":"161","author":"FA Karreth","year":"2015","unstructured":"Karreth, F. A. et al. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell 161(2), 319\u2013332 (2015).","journal-title":"Cell"},{"issue":"3","key":"3235_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092099","volume":"9","author":"Y Hu","year":"2014","unstructured":"Hu, Y., Zhu, Q. & Tang, L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS ONE 9(3), e92099 (2014).","journal-title":"PLoS ONE"},{"issue":"3","key":"3235_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3892\/or.2015.4104","volume":"34","author":"J Yang","year":"2015","unstructured":"Yang, J., Liu, X., Yuan, X. & Wang, Z. miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker. Oncol. Rep. 34(3), 1415\u20131423 (2015).","journal-title":"Oncol. Rep."},{"issue":"2","key":"3235_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.canlet.2015.08.029","volume":"369","author":"DB Shi","year":"2015","unstructured":"Shi, D. B. et al. C\/EBPalpha-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett. 369(2), 376\u2013385 (2015).","journal-title":"Cancer Lett."},{"key":"3235_CR14","doi-asserted-by":"publisher","first-page":"15517","DOI":"10.1007\/s13277-015-3850-z","volume":"37","author":"J Luo","year":"2016","unstructured":"Luo, J. et al. Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3. Tumour Biol. 37, 15517\u201315524 (2016).","journal-title":"Tumour Biol."},{"key":"3235_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep11650","volume":"5","author":"Y Gong","year":"2015","unstructured":"Gong, Y. et al. The role of miR-100 in regulating apoptosis of breast cancer cells. Sci. Rep. 5, 11650 (2015).","journal-title":"Sci. Rep."},{"issue":"2","key":"3235_CR16","first-page":"545","volume":"5","author":"XD Yang","year":"2015","unstructured":"Yang, X. D. et al. Role of miR-100 in the radioresistance of colorectal cancer cells. Am. J. Cancer Res. 5(2), 545\u2013559 (2015).","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"3235_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064434","volume":"8","author":"Y Jin","year":"2013","unstructured":"Jin, Y. et al. MicroRNA-99 family targets AKT\/mTOR signaling pathway in dermal wound healing. PLoS ONE 8(5), e64434 (2013).","journal-title":"PLoS ONE"},{"issue":"1","key":"3235_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0411-9","volume":"30","author":"J Sun","year":"2013","unstructured":"Sun, J. et al. MicroRNA-99a\/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med. Oncol. 30(1), 411 (2013).","journal-title":"Med. Oncol."},{"issue":"5","key":"3235_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cmi.12709","volume":"19","author":"Y Lin","year":"2017","unstructured":"Lin, Y. et al. The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R\/PI3K\/Akt\/mTOR\/ULK1 signaling-induced autophagy. Cell Microbiol. 19(5), 1\u201315 (2017).","journal-title":"Cell Microbiol."},{"issue":"2","key":"3235_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jcb.24965","volume":"116","author":"SH Yu","year":"2015","unstructured":"Yu, S. H., Zhang, C. L., Dong, F. S. & Zhang, Y. M. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J. Cell Biochem. 116(2), 268\u2013276 (2015).","journal-title":"J. Cell Biochem."},{"issue":"4","key":"3235_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-10-1031","volume":"71","author":"D Sun","year":"2011","unstructured":"Sun, D. et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 71(4), 1313\u20131324 (2011).","journal-title":"Cancer Res."},{"issue":"2","key":"3235_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ymeth.2012.07.004","volume":"58","author":"JH Yoon","year":"2012","unstructured":"Yoon, J. H., Srikantan, S. & Gorospe, M. MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. Methods 58(2), 81\u201387 (2012).","journal-title":"Methods"},{"issue":"17","key":"3235_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1089\/ars.2017.7486","volume":"30","author":"K Wu","year":"2018","unstructured":"Wu, K. et al. Targeting of PP2Cdelta By a small molecule C23 inhibits high glucose-induced breast cancer progression in vivo. Antioxid. Redox Signal. 30(17), 1983\u20131998 (2018).","journal-title":"Antioxid. Redox Signal."},{"key":"3235_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejmech.2014.01.041","volume":"75","author":"N Samaan","year":"2014","unstructured":"Samaan, N. et al. Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents. Eur. J. Med. Chem. 75, 123\u2013131 (2014).","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"3235_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1073\/pnas.0810956106","volume":"106","author":"A Dubrovska","year":"2009","unstructured":"Dubrovska, A. et al. The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl Acad. Sci. USA 106(1), 268\u2013273 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"5","key":"3235_CR26","first-page":"1602","volume":"5","author":"P Xia","year":"2015","unstructured":"Xia, P. & Xu, X. Y. PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am. J. Cancer Res. 5(5), 1602\u20131609 (2015).","journal-title":"Am. J. Cancer Res."},{"issue":"41","key":"3235_CR27","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1073\/pnas.0702596104","volume":"104","author":"J Zhou","year":"2007","unstructured":"Zhou, J. et al. Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104(41), 16158\u201316163 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"6","key":"3235_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000121","volume":"7","author":"H Korkaya","year":"2009","unstructured":"Korkaya, H. et al. Regulation of mammary stem\/progenitor cells by PTEN\/Akt\/beta-catenin signaling. PLoS Biol. 7(6), e1000121 (2009).","journal-title":"PLoS Biol."},{"issue":"D1","key":"3235_CR29","doi-asserted-by":"publisher","first-page":"D231","DOI":"10.1093\/nar\/gkv1270","volume":"44","author":"MD Paraskevopoulou","year":"2016","unstructured":"Paraskevopoulou, M. D. et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 44(D1), D231\u2013D238 (2016).","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"3235_CR30","doi-asserted-by":"publisher","first-page":"R858","DOI":"10.1016\/j.cub.2010.08.052","volume":"20","author":"MS Ebert","year":"2010","unstructured":"Ebert, M. S. & Sharp, P. A. Emerging roles for natural microRNA sponges. Curr. Biol. 20(19), R858\u2013R861 (2010).","journal-title":"Curr. Biol."},{"issue":"7301","key":"3235_CR31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/nature09144","volume":"465","author":"L Poliseno","year":"2010","unstructured":"Poliseno, L. et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465(7301), 1033\u20131038 (2010).","journal-title":"Nature"},{"issue":"2","key":"3235_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2011.09.029","volume":"147","author":"Y Tay","year":"2011","unstructured":"Tay, Y. et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147(2), 344\u2013357 (2011).","journal-title":"Cell"},{"issue":"30","key":"3235_CR33","doi-asserted-by":"publisher","first-page":"48206","DOI":"10.18632\/oncotarget.10195","volume":"7","author":"R Hatem","year":"2016","unstructured":"Hatem, R. et al. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget 7(30), 48206\u201348219 (2016).","journal-title":"Oncotarget"},{"issue":"1","key":"3235_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1107-2","volume":"21","author":"W Cao","year":"2019","unstructured":"Cao, W. et al. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 21(1), 29 (2019).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"3235_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20121456","volume":"450","author":"LM Graves","year":"2013","unstructured":"Graves, L. M., Duncan, J. S., Whittle, M. C. & Johnson, G. L. The dynamic nature of the kinome. Biochem. J. 450(1), 1\u20138 (2013).","journal-title":"Biochem. J."},{"issue":"5","key":"3235_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak, A. M. et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16(5), 1273\u20131286 (2016).","journal-title":"Cell Rep."},{"issue":"5827","key":"3235_CR37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039\u20131043 (2007).","journal-title":"Science"},{"key":"3235_CR38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1593\/neo.09230","volume":"11","author":"V Pillay","year":"2009","unstructured":"Pillay, V. et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11, 448\u2013458 (2009).","journal-title":"Neoplasia"},{"issue":"10","key":"3235_CR39","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-10-0163","volume":"70","author":"AM Xu","year":"2010","unstructured":"Xu, A. M. & Huang, P. H. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 70(10), 3857\u20133860 (2010).","journal-title":"Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03235-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03235-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03235-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:01:08Z","timestamp":1670256068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03235-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["3235"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03235-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1052"}}